Letters
Trans-Pacific Partnership
Will Pharmac become a victim of its own success?
BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d4908 (Published 02 August 2011) Cite this as: BMJ 2011;343:d4908
- Rachel H Foster, research fellow1,
- Nick Wilson, associate professor1
- 1Department of Public Health, University of Otago, Wellington, New Zealand,
- rachel.foster-russell{at}otago.ac.nz
Moynihan’s article summarises well the issues surrounding New Zealand’s drug funding authority Pharmac and the Trans-Pacific Partnership trade agreement currently being negotiated with the US.1 Why are US drug companies lobbying against Pharmac when the New Zealand drug market is insignificant in global terms? Pharmac’s success has probably made it a target.
Pharmac operates within a …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.